1. A novel genetic variant in PTGS1 affects N-glycosylation of cyclooxygenase-1 causing a dominant-negative effect on platelet function and bleeding diathesis
- Author
-
Harriet E. Allan, Jesús María Hernández-Rivas, Agustín Rodriguez-Alén, Elena Almarza, Maria Luisa Lozano, Tania Maffucci, Javier Corral, Carlos Damián, Irene Martínez-Martínez, Vicente Vicente, Nuria Revilla, Melissa V. Chan, Ignacio Casas-Aviles, Rocío Benito, Timothy D. Warner, Verónica Palma-Barqueros, José María Bastida, Matthew L. Edin, Darryl C. Zeldin, Nuria Bermejo, Natalia Bohdan, Cristina Mesa-Núñez, José Rivera, Antonia Miñano, José Padilla, Maria Eugenia de la Morena, José Ramón González-Porras, Ana Marín-Quílez, Marilena Crescente, Fundación Mutua Madrileña, Fundación Séneca, Instituto de Salud Carlos III, Junta de Castilla y León, British Heart Foundation, and Sociedad Española de Trombosis y Hemostasia
- Subjects
medicine.medical_specialty ,Mutation ,Glycosylation ,biology ,business.industry ,PTGS1 ,Heterozygote advantage ,Hematology ,medicine.disease ,medicine.disease_cause ,Bleeding diathesis ,chemistry.chemical_compound ,Endocrinology ,N-linked glycosylation ,chemistry ,Internal medicine ,medicine ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Platelet ,Cyclooxygenase ,business ,circulatory and respiratory physiology - Abstract
During platelet activation, arachidonic acid (AA) is released from membrane phospholipids and metabolized to thromboxane A2 (TXA2) through the actions of cyclooxygenase-1 (COX-1) and TXA2 synthase. Note, TXA2 binds to the platelet TXA2 receptor, causing shape change, secretion and platelet aggregation.1 Also, COX-1 (599aa; 70 kDa) has cyclooxygenase and peroxidase activities and it is functionally active as a homodimer, with each COX-1 monomer consisting of four highly conserved domains: an N-terminal signal peptide, a dimerization domain, a membrane-binding domain (MBD) and a large C-terminal catalytic domain2 (Figure 1A). Irreversible COX-1 inhibition by aspirin is a widely established anti-platelet therapy in cardiovascular disease., Fundación Mutua Madrileña, Grant/Award Number: AP172142019; Fundación Séneca, Grant/Award Number: 19873/GERM/15; Gerencia Regional de Salud, Grant/Award Numbers: 1647/A/17, 2061A/19; Instituto de Salud Carlos III (ISCIII) & Feder, Grant/Award Numbers: CB15/00055, PI17/01966, PI18/00598, PI20/00926, PI17/01311; Junta de Castilla y León; British Heart Foundation, Grant/Award Number: PG/17/40/33028; Ayuda a Grupos de Trabajo en Patología Hemorrágica; Premio López Borrasca 2019; Sociedad Española de Trombosis y Hemostasia.
- Published
- 2021